News
Allon Therapeutics to present at International CNS Disease Congress
VANCOUVER, June 21, 2007— Allon Therapeutics Inc. (the “Corporation”) (TSX:NPC), the Neuroprotection CompanyTM, announced that the Company has been invited to present Allon’s clinical progress and strategy for AL-108 at the 3rd Annual CNS Diseases Congress, June 25th to 26th, 2007, located at the Hilton Boston Back Bay Hotel, in Boston Massachusetts. The presentation by Dr. Bruce Morimoto, Allon’s VP of Drug Development, is titled “Neuroprotection by AL-108, an Intranasal Peptide” and will take place on Monday June 25th at 9:30am EST.
Dr. Morimoto’s plenary presentation will address and illustrate the neuroprotective effect of Allon’s drug, AL-108 and explain the development strategy behind the two Phase II clinical trials, one for Alzheimer’s disease and one for schizophrenia-related cognitive impairment. Recently published data showed that Allon’s product candidate AL-108 significantly reduces the accumulation of amyloid peptide and the hyperphosphorylation of tau protein in the brain, two pathological hallmarks of Alzheimer’s.
“One of the challenges of neuropeptide drug development is understanding the mechanism and kinetics of how the drugs work, something Allon has repeatedly demonstrated over the course of the last two years,” said Dr. Morimoto. “Together, these results showed that AL-108 is available to its pharmacological target compartment to exert its potent neuroprotective effects.”
AL-108 is currently being evaluated in a Phase II efficacy trial as part of Allon's Alzheimer's program. This trial is expected to complete enrolment at the end of 2007. Early in 2007, AL-108 was selected by the National Institute of Mental Health funded project TURNS (Treatment Unit for Research on Neurocognition and Schizophrenia) for another Phase II efficacy trial evaluating it as a treatment for schizophrenia-related cognitive impairment.
CNS Congress Conference Overview
The 3rd Annual CNS Diseases Congress will feature presentations from industrial and academic researchers from around the world, who are making important contributions to the current body of knowledge in the CNS Diseases area. Along with the latest approaches and technologies to the discovery and development of CNS drugs, this congress will specifically highlight and target the latest in Psychiatric Disorders and Alzheimer’s Disease.
The conference website can be viewed here
About Allon
Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon has 3 Phase II human efficacy trials underway pursuing three large underserved markets: Alzheimer's disease, schizophrenia and cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuroprotection CompanyTM) and based in Vancouver. For additional information please visit the company's website: www.allontherapeutics.com
Forward Looking Statements
There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words “believes,” “may,” “plans,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Allon’s stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Allon’s products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
- 30 -
FOR FURTHER INFORMATION PLEASE CONTACT:
Allon Therapeutics Inc. - Investor and Media Contact
Aaron Keay
Manager, Investor Relations
(604) 742-2540 or Cell: (604) 323-6911
Email: akeay@allontherapeutics.com
Website: www.allontherapeutics.com
